<DOC>
	<DOC>NCT00992160</DOC>
	<brief_summary>This study is a 28-day polysomnographic and subjective assessment of oral Vestipitant 15mg/day for treatment of Primary Insomnia in adults outpatients.</brief_summary>
	<brief_title>Vestipitant 28-day Tolerance Study</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>Male and female aged 1864 years inclusively with Diagnosis of Primary Insomnia according to Diagnostic and Statistical Manual of Mental Disorders Text Revision (DSMIVTR) criteria 307.42 PSG variables collected during 2consecutive PSG screening nights falling as follows: TST between 240420 mins inclusive (both nights) LPS (Latency to Persistent Sleep): mean not less than 20mins, each night not less than 15 mins WASO (Wake After Sleep Onset): mean not less than 60mins, each night not less than 45mins Women: non child bearing potential or if child bearing potential agree on Contraceptive Methods listed in Protocol clinically significant Psychiatric and neurological disorders (sleep disorders other than Primary Insomnia, history of alcohol orother substance abuse or dependnce); nightshift or rotating shiftwork; Lifestyle habits in agreement with Protocol requirement: caffeine alcohol intake and smoke healthy according to GSK criteria laboratory and ECG limits set in the Protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Polysomnography (PSG)</keyword>
	<keyword>Adults</keyword>
	<keyword>Primary Insomnia</keyword>
</DOC>